Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy + regorafenib + PD-1 inhibitor for third-line MSS metastatic colorectal cancer
ChiCTR2500104322Phase 2Not yet recruiting
- Sponsor
- Southwest Hospital of Army Medical University
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib in colorectal adenocarcinoma, sponsored by Southwest Hospital of Army Medical University. Primary endpoint: Objective response rate (ORR). Planned start Jun 2025; status: not yet recruiting.
02
Drugs
regorafenib
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500104322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104322.